Allarity Therapeutics, Inc. Income (Loss) Attributable to Parent, before Tax
Allarity Therapeutics, Inc. (ALLR) reported Income (Loss) Attributable to Parent, before Tax of -$4.45 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2023-11-14
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for the quarter ending 2023-09-30 was -$4.45M.
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for the quarter ending 2023-06-30 was -$2.38M.
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for the quarter ending 2023-03-31 was -$3.35M.
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for the quarter ending 2022-12-31 was -$3.14M.
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for fiscal 2022 was -$17.58M.
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for fiscal 2021 was -$26.52M.
- Allarity Therapeutics, Inc. income (loss) attributable to parent, before tax for fiscal 2020 was -$6.42M.
| Period end | Income (Loss) Attributable to Parent, before Tax 3 month | Income (Loss) Attributable to Parent, before Tax 3 month as first filed | Income (Loss) Attributable to Parent, before Tax 6 month | Income (Loss) Attributable to Parent, before Tax 9 month | Income (Loss) Attributable to Parent, before Tax 9 month as first filed | Income (Loss) Attributable to Parent, before Tax 12 month |
|---|---|---|---|---|---|---|
| 2023-09-30 | -$4.45M 10-Q · filed 2023-11-14 | -$6.83M derived: sum of 2 quarters · filed 2023-11-14 | -$10.18M 10-Q · filed 2023-11-14 | -$13.32M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2023-06-30 | -$2.38M 10-Q · filed 2023-08-14 | -$5.73M 10-Q · filed 2023-08-14 | -$8.87M derived: sum of 3 quarters · filed 2023-08-14 | -$13.90M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2023-03-31 | -$3.35M 10-Q · filed 2023-05-11 | -$6.49M derived: sum of 2 quarters · filed 2023-05-11 | -$11.53M derived: sum of 3 quarters · filed 2023-11-14 | -$16.62M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-12-31 | -$3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$8.17M derived: sum of 2 quarters · filed 2023-11-14 | -$13.27M derived: sum of 3 quarters · filed 2023-11-14 | -$17.58M 10-K · filed 2023-03-13 | ||
| 2022-09-30 | -$5.03M 10-Q · filed 2023-11-14 | -$10.13M derived: sum of 2 quarters · filed 2023-11-14 | -$14.44M 10-Q · filed 2023-11-14 | -$31.22M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$5.10M 10-Q · filed 2023-08-14 | -$9.41M 10-Q · filed 2023-08-14 | -$26.19M derived: sum of 3 quarters · filed 2023-08-14 | -$27.50M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$4.31M 10-Q · filed 2023-05-11 | -$21.09M derived: sum of 2 quarters · filed 2023-05-11 | -$22.41M derived: sum of 3 quarters · filed 2023-05-11 | -$27.77M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$16.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$18.10M derived: sum of 2 quarters · filed 2023-03-13 | -$23.46M derived: sum of 3 quarters · filed 2023-03-13 | -$26.52M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | -$1.32M 10-Q · filed 2022-11-14 | $1.27M 10-Q · filed 2021-11-23 | -$6.68M derived: sum of 2 quarters · filed 2022-11-14 | -$9.73M 10-Q · filed 2022-11-14 | -$7.05M 10-Q · filed 2021-11-23 | -$11.35M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$5.37M 10-Q · filed 2022-10-07 | -$8.42M 10-Q · filed 2022-10-07 | -$10.03M derived: sum of 3 quarters · filed 2022-10-07 | -$11.48M derived: sum of 4 quarters · filed 2022-10-07 | ||
| 2021-03-31 | -$3.05M 10-Q · filed 2022-05-27 | -$4.67M derived: sum of 2 quarters · filed 2022-05-27 | -$6.11M derived: sum of 3 quarters · filed 2022-05-27 | |||
| 2020-12-31 | -$1.61M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | -$3.06M derived: sum of 2 quarters · filed 2022-05-17 | -$6.42M 10-K · filed 2022-05-17 | |||
| 2020-09-30 | -$1.45M 10-Q/A · filed 2022-05-17 | -$1.65M 10-Q · filed 2021-11-23 | -$4.81M 10-Q/A · filed 2022-05-17 | -$5.42M 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |